At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

In a phase III trial, pre-op MRI did not reduce locoregional recurrences or improve survival among women with early-stage ...

Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

Is omission of the sentinel lymph node biopsy safe in early breast cancer in patients treated with breast conserving therapy ...

Variance in incidence seen across cancer types, but consistently increased with later stage at initial diagnosis.

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly ...

RT consisted of a conventionally fractionated regimen, with the delivery of a total dose of 60 Gy in 6 weeks, in a once-daily schedule of 2 Gy per fraction for a total of 30 fractions. Patients were ...

According to a Cleveland Clinic-issued statement, researchers with the institution have announced the final results of a ...